目的 探讨分析体外高频热疗在早中期乳腺癌术后化疗中的应用.方法 选取2020年4月-2021年1月连续纳入早中期乳腺癌术后患者80例,早中期乳腺癌切除术后患者按1:1比例随机分为两组,单纯化疗组接受AC→T方案化疗8周期,化疗联合热疗组接受AC→T方案化疗8周期(同单纯化疗组)+乳腺癌切除局部胸壁体外高频热疗,对其疗效进行了分析,以证实体外高频热疗法与术后化疗相结合的疗效.计算无病生存期(DFS,disease-free survivsl),应用流式细胞仪观察免疫指标CD3+、CD4+、CD8+、CD4+/CD8+以及NK细胞的变化,统计治疗期间的并发症,主要包括化疗不良反应如心脏毒性、恶心、呕吐、骨髓抑制和热疗并发症如烫伤、皮下脂肪硬结等.结果 化疗联合热疗组与单纯化疗组相比,观察1年无病生存率无明显提高,两组间无显著差异(P>0.05);两组CD3+、CD4+、CD8+、CD4+/CD8+、自然杀伤细胞NK细胞的表达均有显著性差异(P<0.05);化疗不良反应、热疗并发症发生率两组相比,差异无显著性(P>0.05).结论 早中期乳腺癌手术后,体外高频热疗法与化疗结合治疗相比单纯化疗,可提高患者免疫状态,治疗并发症无变化,但观察1年暂未看到疗效,可能与观察时间有限有关,笔者将继续观察两组患者后续2年、5年无病生存率情况,以进一步明确疗效.

目的:探讨吉西他滨、顺铂方案双途径化疗联合体外高频深部热疗治疗局部晚期非小细胞肺癌的临床效果.方法:回顾分析2017年10月-2019年1月笔者所在医院收治的局部晚期非小细胞肺癌患者80例,按治疗方式分组,对照组40例接受常规化疗,研究组40例接受吉西他滨、顺铂方案双途径化疗联合体外高频深部热疗.比较两组治疗效果、生存率及不良反应发生率.结果:研究组总有效率为85.71％,高于对照组的60.00％(P<0.05).随访3、6个月,研究组生存率分别为80.00％、70.00％,均高于对照组的55.00％、37.50％(P<0.05).研究组不良反应发生率为25.00％,对照组不良反应发生率为26.67％,差异无统计学意义(P>0.05).结论:局部晚期非小细胞肺癌患者接受吉西他滨、顺铂方案双途径化疗联合体外高频深部热疗方式治疗,可提升生存率,且近期效果理想,安全性高.

目的 分析高频热疗配合化疗治疗晚期复发乳腺癌的临床效果.方法 60例晚期复发乳腺癌患者,随机分为对照组和观察组,每组30例.对照组患者采取化疗方案进行治疗,观察组患者采取高频热疗联合化疗方案进行治疗.比较两组患者临床疗效、治疗前后免疫学指标[CD3+、CD4+、CD8+、CD4+/CD8+、自然杀伤细胞(NK细胞)]水平及不良反应发生情况.结果 观察组患者的治疗总有效率83.33％ 高于对照组的60.00％,差异具有统计学意义(P<0.05).治疗前,两组患者CD3+、CD4+、CD8+、CD4+/CD8+、NK细胞水平比较差异无统计学意义(P>0.05);治疗后,两组患者CD3+、CD4+、CD8+、CD4+/CD8+、NK细胞水平均优于本组治疗前,且观察组优于对照组,差异均具有统计学意义(P<0.05).两组患者的心脏毒性、恶心呕吐、骨髓抑制、其他不良反应发生率比较差异均无统计学意义(P>0.05).结论 高频热疗配合化疗治疗晚期复发乳腺癌能够获得良好的临床效果.

目的:探讨需行宫颈癌手术的早中期宫颈癌患者接受紫杉醇联合顺铂新辅助化疗治疗的临床效果.方法:选取本院于2017年1月1日～2019年6月30日收治的100例早中期宫颈癌患者为研究对象,根据治疗方式不同分为50例参照组与50例试验组.参照组直接进行手术治疗,试验组在手术前采用紫杉醇联合顺铂新辅助化疗,两组术后均给予补充化疗.观察两组临床疗效、治疗前后的生活质量评分以及不良反应发生情况.结果:两组治疗前生活质量评分对比差异无统计学意义(P＞0.05),试验组手术成功率(96.00％)明显高于参照组(84.00％);试验组生活质量评分为(77.69±5.06)分,参照组生活质量评分为(69.57±2.86)分,试验组明显高于参照组;试验组的不良反应发生率(16.00％)明显低于参照组(34.00),P＜0.05.结论:给予需行宫颈癌手术的早中期宫颈癌患者紫杉醇联合顺铂新辅助化疗治疗,能够提高临床疗效,改善生活质量,降低不良反应发生率,临床价值较高,值得推广.

Objective To investigate clinical characteristics and prognosis of lung cancer complicated with phlebothrombosis. Methods Analysis was made on general data, location of phlebothrombosis, symptoms and treatment status in 120 lung cancer complicated with phlebothrombosis patients. Occurrence of thrombus was summarized in 3, 6, 9, 12 months after diagnosis of lung cancer. Results In the pulmonary thromboembolism group, there were respectively 36, 40, 44, 45, 52 cases with thromboembolism after 3, 6, 9, 12, and over 12 months of diagnosis of lung cancer. Those numbers in the venous thromboembolism group were 51, 53, 54, 55, 68 cases. Their differences had no statistical significance (P>0.05). In the chemotherapy group, there were respectively 28, 36, 39, 39, 48 cases with thromboembolism after 3, 6, 9, 12, and over 12 months of diagnosis of lung cancer. Those numbers in the operation group were 21, 25, 25, 25, 28 cases. Their differences had no statistical significance (P>0.05). Pulmonary thromboembolism group had death cases as in 22, 30, 33, 33, 39 cases after 3, 6, 9, 12, and over 12 months of diagnosis of venous thromboembolism. Those numbers of venous thromboembolism group were 17, 24, 28, 30, 40 cases. Their differences had no statistical significance (P>0.05). Conclusion Lung cancer patients have high incidence of venous thromboembolism, which has its high-incidence period in 3~6 months after diagnosis. Those patients of lung cancer complicated with venous thromboembolism have high mortality rate, and most of them die within 1 year. Active prevention and treatment of venous thromboembolism contain important significance for prolonging life time of lung cancer patients.

Objective To observe the efficacy and safety of RNA II for injection in patients with advanced gastrointestinal cancer. Methods 80 patients with advanced gastrointestinal cancer were single-blind randomized into group RNA II and control group. The simple chemotherapy for control group, using RNA II 200 mg/day, 45 days (one course) for the group RNAII on the base of chemotherapy, and then detect the of variation of T-cell subsets, the leukocytes, the incidence of adverse side effects and evaluate the life quality of the patients through the Karnofsky score. Results ①The positive rate of CD3, CD4 , CD56 in group RNAII were higher than the control group (P<0.05).②The decreased level of WBC and the ratio of adverse events in group RNAII were lower than the control group (P<0.05). ③The promotion ratio of Karnofsky score in group RNAII(57.5%) was higher than control group(42.5%). Conclusion ①RNA II can stimulate the maturation of T-cell, improve the immune function of the patients.②RNA II can reduce the decrease of WBC, the side effects of chemotherapy.③RNA II combined with chemotherapy can improve the quality of life effectively.